The company had not issued any dividends in recent years.
Please consider monitoring Dermata Therapeutics on a daily basis if you are holding a position in it. Dermata Therapeutics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Dermata Therapeutics stock to be traded above the $1 level to remain listed. If Dermata Therapeutics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Dermata Therapeutics
financial leverage refers to using borrowed capital as a funding source to finance Dermata Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Dermata Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Dermata Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Dermata Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Dermata Therapeutics's total debt and its cash.
At present, Dermata Therapeutics'
Change In Cash is projected to decrease significantly based on the last few years of reporting. . To perform a cash flow analysis of Dermata Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Dermata Therapeutics is receiving and how much cash it distributes out in a given period. The Dermata Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Roughly 100.0 percent of Dermata Therapeutics outstanding shares are held by regular investors with 0.0 (percent) owned by
insiders and only 0.0 % by
other corporate entities.
Ownership Breakdown
| Retail Investors | 100.0 |
| Insiders | 0.0 |
| Institutions | 0.0 |
Our take on today Dermata Therapeutics rise
Current potential upside is at 8.7. Dermata Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Dermata Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Dermata Therapeutics volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Dermata Therapeutics' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Dermata Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Dermata Therapeutics Implied Volatility
Dermata Therapeutics' implied volatility exposes the market's sentiment of Dermata Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Dermata Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Dermata Therapeutics stock will not fluctuate a lot when Dermata Therapeutics' options are near their expiration.
The Bottom Line
Whereas some companies within the biotechnology industry are still a little expensive, even after the recent corrections, Dermata Therapeutics may offer a potential longer-term growth to investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither trade nor short any shares of Dermata Therapeutics at this time. The Dermata Therapeutics risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Dermata Therapeutics.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEllen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Dermata Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com